About Akoya Biosciences Inc
Ticker
info
AKYA
Trading on
info
NASDAQ
ISIN
info
US00974H1041
Industry
info
Medical Instruments & Supplies
Sector
info
Healthcare
CEO
info
Brian McKelligon
Headquarters
info
100 Campus Drive, Marlborough, MA, United States, 01752
Employees
info
205
Website
info
akoyabio.com
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$76.7M
P/E ratio
info
-
EPS
info
-$1.12
Dividend Yield
info
0.00%
Beta
info
1.32
Forward P/E ratio
info
0
EBIDTA
info
$-33.5M
Ex dividend date
info
-
Price & volume
Market cap
info
$76.7M
Average daily volume
info
0.3M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
0.94
Price to book
info
10.95
Earnings
EPS
info
-$1.12
EPS estimate (current quarter)
info
-$0.16
EPS estimate (next quarter)
info
-$0.21
EBITDA
info
$-33.5M
Revenues (TTM)
info
$81.7M
Revenues per share (TTM)
info
$1.65
Technicals
Beta
info
1.32
52-week High
info
$4.79
52-week Low
info
$1.39
50-day moving average
info
$2.20
200-day moving average
info
$2.44
Short ratio
info
6.77
Short %
info
8.22%
Management effectiveness
ROE (TTM)
info
180.45%
ROA (TTM)
info
16.86%
Profit margin
info
67.79%
Gross profit margin
info
$47.9M
Operating margin
info
26.84%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
19.40%
Share stats
Outstanding Shares
info
49.8M
Float
info
15.4M
Insiders %
info
67.21%
Institutions %
info
69.85%
Analyst Insights & forecasts
info

38% Buy

62% Hold

0% Sell

Based on information from 8 analysts.

Average price target

info
$3.14
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.48
-$0.29
65.52%
Q1 • 24Beat
-$0.27
-$0.27
-
Q2 • 24Beat
-$0.18
-$0.20
10.70%
Q3 • 24Beat
-$0.17
-$0.16
4.62%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$18.8M
$-10.5M
55.98%
Q3 • 24
$21.3M
$-8.2M
38.41%
Q4 • 24
13.45%
22.16%
31.39%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$130M
$116M
89.51%
Q3 • 24
$125M
$117M
93.92%
Q4 • 24
3.82%
0.92%
4.93%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-9.3M
$13M
$-0.2M
$-9.7M
Q3 • 24
$-3M
$2.7M
$-0.5M
$-4M
Q4 • 24
67.78%
79.31%
224.00%
58.47%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Neutral

+1.5

-0.30

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Akoya Biosciences Inc share?
Collapse

Akoya Biosciences Inc shares are currently traded for undefined per share.

How many shares does Akoya Biosciences Inc have?
Collapse

Akoya Biosciences Inc currently has 49.8M shares.

Does Akoya Biosciences Inc pay dividends?
Collapse

No, Akoya Biosciences Inc doesn't pay dividends.

What is Akoya Biosciences Inc 52 week high?
Collapse

Akoya Biosciences Inc 52 week high is $4.79.

What is Akoya Biosciences Inc 52 week low?
Collapse

Akoya Biosciences Inc 52 week low is $1.39.

What is the 200-day moving average of Akoya Biosciences Inc?
Collapse

Akoya Biosciences Inc 200-day moving average is $2.44.

Who is Akoya Biosciences Inc CEO?
Collapse

The CEO of Akoya Biosciences Inc is Brian McKelligon.

How many employees Akoya Biosciences Inc has?
Collapse

Akoya Biosciences Inc has 205 employees.

What is the market cap of Akoya Biosciences Inc?
Collapse

The market cap of Akoya Biosciences Inc is $76.7M.

What is the P/E of Akoya Biosciences Inc?
Collapse

The current P/E of Akoya Biosciences Inc is null.

What is the EPS of Akoya Biosciences Inc?
Collapse

The EPS of Akoya Biosciences Inc is -$1.12.

What is the PEG Ratio of Akoya Biosciences Inc?
Collapse

The PEG Ratio of Akoya Biosciences Inc is null.

What do analysts say about Akoya Biosciences Inc?
Collapse

According to the analysts Akoya Biosciences Inc is considered a hold.